PCSK9 and hyperlipidemia: Modulatory biomarkers such as proprotein convertase subtilisin/kexin type 9 (PCSK9), angiopoietin-like protein (ANGPTL), and fibroblast growth factors (FGFs) play a significant role in modulating the risk of hypothyroidism-associated hyperlipidemia [57].